July 18, 2025CA A Cancer Journal for CliniciansOpen Access

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

View Full Paper

Ask AI

Bookmark

Authors

MBMaxime BorgeaudUniversity of Geneva TOTimothée OlivierUniversity of Geneva JBJair BarTel Aviv University

Discussion

Member takes

Implication

Review highlights breakthroughs in managing EGFR-mutant non-small cell lung cancer, suggesting precise treatment based on biomarkers and addressing toxicity issues.

Key Points

Targeted tyrosine kinase inhibitors have improved survival for patients with EGFR-mutant nonsmall cell lung cancer.
Emerging biomarkers like circulating tumor DNA may refine treatment decisions for better patient outcomes.
Combination strategies in metastatic settings have shown increased progression-free survival despite higher toxicity.
Understanding resistance mechanisms to EGFR TKIs offers new therapeutic options to enhance care for patients.

Cite This Study

Borgeaud et al. (2025) studied this question.

synapsesocial.com/papers/689a02c9e6551bb0af8cce5e https://doi.org/10.3322/caac.70024

View Full Paper

Ask AI

Bookmark

Implication

Review highlights breakthroughs in managing EGFR-mutant non-small cell lung cancer, suggesting precise treatment based on biomarkers and addressing toxicity issues.

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

Discussion

Member takes

Implication

Key Points

Cite This Study

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider